Quest Pharmatech Inc. (QPTFF)
Market Closed
10 Aug, 20:00
OTC PINK OTC PINK Primary 
TSX-V $
0. 02
0
0%
$
3.38M Market Cap
- P/E Ratio
- Div Yield
10,000 Volume
0 Eps
$ 0.02
Previous Close Want to track QPTFF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
QPTFF closed yesterday higher at $0.02, an increase of 0% from Friday's close, completing a monthly decrease of -33.3333% or -$0.01. Over the past 12 months, QPTFF stock lost -50%.
QPTFF is not paying dividends to its shareholders.
The last earnings report, released on May 28, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.0015%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).
Quest Pharmatech Inc. (QPTFF) FAQ
What is the stock price today?
The current price is $0.02.
On which exchange is it traded?
Quest Pharmatech Inc. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is QPTFF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 3.38M.
Has Quest Pharmatech Inc. ever had a stock split?
No, there has never been a stock split.
Quest Pharmatech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ragupathy Madiyalakan CEO | OTC PINK Exchange | 74836M106 CUSIP |
| CA Country | 3 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Quest PharmaTech Inc. is a pharmaceutical company focused on the development of innovative therapeutics to address specific types of cancer. By concentrating its efforts on targeted cancer therapy applications, the company aims to advance its research and development to bring forward novel solutions for cancer treatment. With its headquarters situated in Edmonton, Canada, Quest PharmaTech is actively involved in progressing its lead product candidates through clinical trials and aims for significant contributions to oncology.
Products and Services
- Mab AR 9.6 against truncated O-glycan on MUC16: This lead product candidate of Quest PharmaTech is positioned for targeted cancer therapy applications. Targeting the truncated O-glycan on MUC16, Mab AR 9.6 represents a pioneering approach in the fight against cancer by attempting to harness the body's own immune system to recognize and attack cancer cells.
- Oregovomab for ovarian cancer: Currently in Phase III clinical trial, Oregovomab is an antibody therapy designed for the treatment of ovarian cancer. It represents an important part of Quest PharmaTech's effort to offer new therapeutic options for ovarian cancer patients, a group in dire need of effective treatments.
- Immunotherapy products for pancreatic cancer: Quest PharmaTech is also engaged in the development, manufacture, and commercialization of immunotherapy products aimed at pancreatic cancer. These products are part of the company's broader strategy to tackle various cancers through immunotherapy, leveraging the body's immune response to fight cancer cells.
- Combinatorial immunotherapeutic products for cancer: The company is exploring the potential of combinatorial immunotherapeutic products that utilize monoclonal antibodies of the immunoglobulin of G and E class. This innovative approach aims to offer a broad spectrum therapy option that could be effective against various types of cancer by enhancing the body's immune response against cancer cells.
Contact Information
Address: 97 Street NW
Phone: +1 780 448 1400
Website: https://www.questpharmatech.com
